학술논문
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Document Type
Article
Author
Zelenetz, Andrew D ; Barrientos, Jacqueline C; Brown, Jennifer R; Coiffier, Bertrand; Delgado, Julio; Egyed, Miklós; Ghia, Paolo; Illés, Árpád; Jurczak, Wojciech; Marlton, Paula; Montillo, Marco; Morschhauser, Franck; Pristupa, Alexander S; Robak, Tadeusz; Sharman, Jeff P; Simpson, David; Smolej, Lukáš; Tausch, Eugen; Adewoye, Adeboye H; Dreiling, Lyndah K; Kim, Yeonhee; Stilgenbauer, Stephan; Hillmen, Peter
Source
In The Lancet Oncology March 2017 18(3):297-311
Subject
Language
ISSN
1470-2045